Table 4.
Characteristics of Cohort 2 SARS-CoV-2–Positive Heart Transplant Population (N = 6)
| Demographics | |
| Age (yrs) | 59.0 (48.3–73.5) |
| Male | 4 (67) |
| Time from Htx (yrs) | 7.8 (3.7–18.3) |
| Risk factors | |
| BMI (kg/m2) | 26.9 (22.7–29.9) |
| Obesity | 2 (33) |
| Arterial hypertension | 4 (67) |
| Dyslipidemia | 2 (33) |
| Diabetes mellitus | 2 (33) |
| Former smoker | 0 (0) |
| Peripheral vascular disease | 0 (0) |
| COPD | 1 (17) |
| Stroke | 0 (0) |
| Malignancy | 2 (33) |
| Dialysis | 0 (0) |
| GFR (ml/min) | 43.5 (39.0–73.5) |
| Previous PCI | 1 (17) |
| CMR | 1 (17) |
| AMR | 0 (0) |
| CAV Score | 0 (0–3) |
| NYHA functional class | |
| I | 4 (66) |
| II | 2 (33) |
| III | 0 |
| IV | 0 |
| LVEF (%) | 58.5 (55.8–62.8) |
| Immunosuppressive therapy | |
| Cyclosporine | 3 (50) |
| Tacrolimus | 1 (17) |
| Prednisone | 3 (50) |
| Mycophenolate | 4 (67) |
| Everolimus | 1 (17) |
| Azathioprine | 0 (0) |
| Anticoagulant therapy | 0 (0) |
| Laboratory results at last follow-up | |
| WBC count (cells per 109/l) | 5.48 (5.11–6.66) |
| Lymphocyte (cells per 109/l) | 1.22 (0.92–1.77) |
| COVID-19 onset | |
| Presenting symptoms | 4 (66) |
| Fever | 4 (66) |
| Cough | 2 (33) |
| Shortness of breath | 2 (33) |
| Myalgia | 2 (33) |
| Headache | 1 (17) |
| Anosmia | 0 (0) |
| Sinusitis | 0 (0) |
| Gastrointestinal | 0 (0) |
| Nasopharyngeal swab test positive | 6 (100) |
| X-ray pneumonia | 1 (17) |
| Fever peak (°C) | 38.1 (37.7–38.4) |
| Duration of fever (days) | 4.8 (4.5–5.0) |
| Duration of symptoms (days) | 6.0 (4.8–7.0) |
| Hospitalization | 1 (17) |
| Modification of immunosuppressive therapy | 1 (17) |
| Antibiotics prophylaxis | 4 (67) |
| Death | 0 (0) |
Values are mean (range) or n (%).
AMR = antibody-mediated rejection; BMI = body mass index; CAV = cardiac allograft vasculopathy; CMR = cardiac magnetic resonance; COPD = chronic obstructive pulmonary disease; GFR = glomerular filtration rate; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association; PCI = percutaneous coronary intervention; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; WBC, white blood cells.